Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$0.96 USD
-0.05 (-4.95%)
Updated Jan 8, 2025 01:46 PM ET
4-Sell of 5 4
B Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CRLBF 0.96 -0.05(-4.95%)
Will CRLBF be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for CRLBF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRLBF
Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Misses Revenue Estimates
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
CRLBF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Universal Health Services (UHS) Q2 Earnings and Revenues Surpass Estimates
QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
Other News for CRLBF
Cresco Labs Is Perhaps The Best Large MSO To Own
Green Thumb Stands Alone. Billions In Debt Coming For MSOs
The Price Is Right: This Weed Real Estate Stock Proves Conservative Strategies Bring Returns
Illinois Cannabis Sales Back On Track In October Hitting $142.3M After Slight September Dip
Pharma-Grade Cannabis Could Hit Walgreens & CVS—But Can The Industry Survive The FDA?